Martin Rogers

Martin Rogers (born 1981) is an Australian bioentrepreneur who has been associated since 2007 with a number of ASX-listed biotechnology companies, including Prima BioMed, which he led from 2007 to 2012.

Background

Rogers attended the University of New South Wales between 1999 and 2004 where he gained a double degree in chemical engineering and computer science. Between 2004 and 2007 he engaged in a number of entrepreneurial pursuits as well as worked at Macquarie Bank.^[1]

Prima BioMed

Rogers was part of an investor group that effectively took control of Prima BioMed in late 2007, when he was appointed a director. At that time Prima had Phase IIa data for its CVac cancer vaccine product, but did not have the funds to progress further. Under Rogers leadership Prima raised A$100m between 2007 and 2012, which included a 2012 IPO on Nasdaq, and took CVac into Phase IIb studies with a runway into Phase III. Prima announced in May 2012 that Rogers would be stepping down as CEO.^[2] He left Prima at the end of August 2012. By the end of of tenure Prima had made it into the S&P/ASX 300.^[3]

Since Prima Biomed

Since 2012 Rogers has been involved at board level in a number of ASX-listed biotech companies, including Cellmid (ASX: CDY) since September 2012;^[4] Rhinomed (ASX: RNO), also since September 2012;^[5] OncoSil Medical (ASX: PSL) since April 2013;^[6] and Actinogen (ASX: ACW), since September 2014.^[7]

References